These include trends in lifestyle patterns (such as smoking, diet, physical activity level), cardiometabolic risk factors, use of guideline-directed medical therapies (RAS inhibitors, statins, sodium-glucose cotransporter-2 [SGLT2] inhibitors, and glucagon-like peptide-1 receptor agonists [GLP1-RAs]), time lags in implementing evidence-based practice, and the feasibility of integrating structured diabetes assessment programs [10], [38], [39]. This evidence concerns the gene GLP1R and diabetes mellitus.